In addition, IGFBP2 can interact with epidermal growth factor receptor via the sequence of 233e257 amino acids, inhibiting the downstream signal transducer and activator of transcription signaling pathway, reducing the promoter activity of srebf1, and downregulating the expression of several genes involved in lipogenesis, thereby alleviating hepatic steatosis (24). This evidence concerns the gene IGFBP2 and fatty liver disease.